Riik: Austraalia
keel: inglise
Allikas: Department of Health (Therapeutic Goods Administration)
meloxicam, Quantity: 15 mg
Medis Pharma Pty Ltd
Meloxicam
Tablet, uncoated
Excipient Ingredients: microcrystalline cellulose; pregelatinised maize starch; lactose monohydrate; maize starch; sodium citrate dihydrate; colloidal anhydrous silica; magnesium stearate
Oral
30 tablets
(S4) Prescription Only Medicine
Meloxicam-DP is indicated for the symptomatic treatment of osteoarthritis and rheumatoid arthritis.
Visual Identification: Pale yellow coloured, circular, flat beveled uncoated tablet, with central breakline on one side and plain on the other side.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius
Licence status A
2007-06-05
MELOXICAM-DP TABLETS CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET Please read this leaflet carefully before you take MELOXICAM-DP tablets. This leaflet answers some common questions about MELOXICAM-DP. It does not contain all available information, nor does it take the place of talking to you doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking MELOXICAM-DP against the benefits this medicine is expected to have for you. You should ask your doctor or pharmacist if you have any questions about MELOXICAM-DP or if you have any trouble before, during or after taking MELOXICAM- DP. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again later. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. WHAT MELOXICAM-DP IS USED FOR MELOXICAM-DP contains the active ingredient meloxicam and is used to treat the symptoms of rheumatoid arthritis and osteoarthritis, which affects the joints causing pain and swelling. MELOXICAM-DP belongs to a family of medicines called Non- Steroidal Anti-inflammatory Drugs (NSAIDs). These medicines work by relieving pain and inflammation. Although MELOXICAM-DP can relieve symptoms such as pain and inflammation, it will not cure your condition. Your doctor may have prescribed MELOXICAM-DP for another reason. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY MELOXICAM-DP HAS BEEN PRESCRIBED TO YOU. This medicine is only available with a doctor’s prescription. There is no evidence that MELOXICAM-DP is addictive. BEFORE YOU TAKE MELOXICAM-DP _WHEN _ _YOU _ _MUST _ _NOT _ _TAKE _ _MELOXICAM-DP_ DO NOT TAKE MELOXICAM-DP IF YOU HAVE AN ALLERGY TO: • The active ingredient, meloxicam, or any of the other ingredients in MELOXICAM-DP. This includes rare inherited conditions of galactose intolerance. • aspirin or any other NSAID medicine. If you are not sure if you have these allergies, you should raise those concerns with your doctor or pharmacist. Some of the symptoms of an allergic reaction m Lugege kogu dokumenti
100621 Meloxicam-DP PI Page 1 of 17 PRODUCT INFORMATION MELOXICAM-DP TABLETS NAME OF MEDICINE : Meloxicam DESCRIPTION: The chemical name of meloxicam is 4-hydroxy-2-methyl-_N_-(5-methyl-1,3-thiazol-2-yl)-2_H_- 1,2-benzothiazine-3-carboxamide 1,1-dioxide. The molecular formula of meloxicam is C 14 H 13 N 3 O 4 S 2 , the molecular weight is 351.4 and the CAS number is 71125-38-7. Meloxicam is a pastel yellow solid with pKa values of 1.09 and 4.18 and a melting point of about 256°C. The substance is practically insoluble in water, soluble in dimethylformamide, slightly soluble in chloroform and acetone, and very slightly soluble in methanol. There are no chiral centres and no polymorphs are formed under normal conditions. Meloxicam-DP is available as tablets containing 7.5 mg and 15 mg of meloxicam. Meloxicam-DP tablets also contain the following excipients: maize starch, lactose, microcrystalline cellulose, pregelatinised maize starch, sodium citrate, colloidal anhydrous silica and magnesium stearate. PHARMACOLOGY: Meloxicam-DP is a non-steroidal anti-inflammatory drug (NSAID) of the enolic acid class, which has shown anti-inflammatory, analgesic and antipyretic properties in animals. Meloxicam showed anti-inflammatory activity in all standard models of inflammation. A common mechanism for the above effects may exist in the ability of meloxicam to inhibit the biosynthesis of prostaglandins, known mediators of inflammation, by inhibition of cyclooxygenase (COX). Comparison of the ulcerogenic dose and the anti-inflammatory effective dose in rat adjuvant arthritis model confirmed a greater therapeutic margin in animals over other NSAIDs (piroxicam, diclofenac, naproxen, flurbiprofen). In rats, meloxicam showed greater inhibitory effect on prostaglandin biosynthesis at the site of inflammation than in the gastric mucosa or the kidney. 100621 Meloxicam-DP PI Page 2 of 17 _Selective inhibition of the cyclooxygenase-2 (COX-2) isoenzyme, relative to COX-1, by _ _meloxicam _ _has _ _been _ _demonstrated _ _in _ _vitro _ _o Lugege kogu dokumenti